The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed

Stock Information for Can-Fite Biopharma Ltd American Depositary Shares each representing two (2)

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Can-Fite Biopharma Ltd American Depositary Shares each representing two (2)

A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
Longeveron Announces Closing of Private Placement of up to $30 Million
Longeveron Announces Private Placement of up to $30 Million
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.